Oncologists often face difficult decisions when managing patients with multiple brain metastases. A landmark phase 3 trial recently examined the benefits of using **stereotactic radiation therapy** versus hippocampal-avoidance whole brain radiation. This study focused on patients with 5 to 20 individual tumors who had not received prior brain-directed radiation therapy.
Impact on Patient Symptom Severity
The trial primary outcome measured changes in symptom severity and daily functioning over six months. Consequently, researchers used the MD Anderson Symptom Inventory-Brain Tumor instrument to track these changes accurately. Results showed that patients receiving stereotactic treatment reported a mean decrease in symptom scores. Conversely, those receiving hippocampal-avoidance whole brain radiation experienced worsening symptoms. This significant difference suggests that focal treatment preserves the patient’s functional status during therapy.
Advantages of Stereotactic Radiation Therapy
In this randomized study, **stereotactic radiation therapy** demonstrated a clinically meaningful improvement in patient-reported outcomes. Therefore, patients maintained better performance status and higher levels of independence in their daily activities. Furthermore, only 3.2% of tumors treated with focal radiation recurred at the initial site. This stands in stark contrast to the 39.5% recurrence rate observed in the whole-brain radiation group. These findings highlight the precision and local control offered by targeted techniques.
Survival and Safety Considerations
Median survival times remained nearly identical between both groups, appearing at roughly 8.4 months. However, the focal radiation group did show a higher cumulative incidence of new brain metastases after one year. Specifically, this group had a 45.4% rate compared to 24.2% in the whole-brain group. Despite this, doctors managed most new lesions successfully with salvage stereotactic treatments. Additionally, the rates of severe adverse events were low and comparable between the two treatment arms.
Frequently Asked Questions
Q1: Does stereotactic radiation therapy improve overall survival for these patients?
No, the study found no significant difference in median survival between stereotactic radiation and hippocampal-avoidance whole brain radiation.
Q2: What is the risk of local recurrence with focal radiation?
The local recurrence rate for individual tumors was remarkably low at 3.2% for stereotactic radiation compared to 39.5% for whole-brain radiation.
Q3: How were new brain metastases managed in the study?
Researchers typically managed new metastases with repeat stereotactic radiation, and only a small fraction of patients eventually required whole-brain radiation.
References
- Aizer AA et al. Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. JAMA. 2026 Feb 19. doi: 10.1001/jama.2026.0076. PMID: 41712219.
- Chan M. From bias to evidence — the rise of stereotactic radiosurgery in brain metastasis treatment. JAMA. 2026. doi: 10.1001/jama.2025.18180.
- Armstrong TS et al. Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage. 2009;37(3):331-340.